Research, Collaboration and Licensing Agreements - Narrative (Details)									1 Months Ended					12 Months Ended				32 Months Ended	37 Months Ended	38 Months Ended	43 Months Ended	50 Months Ended	63 Months Ended	68 Months Ended	73 Months Ended	84 Months Ended	86 Months Ended	96 Months Ended	124 Months Ended
	Nov. 26, 2018 USD ($) Agreement	Oct. 23, 2018 USD ($)	May 30, 2018 USD ($)	Nov. 13, 2017 USD ($)	Sep. 26, 2016 USD ($)	Apr. 21, 2016 USD ($)	Dec. 01, 2015 USD ($)	Dec. 23, 2014 USD ($) program	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Nov. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Jul. 31, 2020 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract assets									$ 0	$ 0				$ 0	$ 0			$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Contract liabilities									32,941,000	32,941,000				32,941,000	32,941,000			32,941,000	32,941,000	32,941,000	32,941,000	32,941,000	32,941,000	32,941,000	32,941,000	32,941,000	32,941,000	32,941,000	32,941,000
Research and development collaborations (note 12)														26,680,000	38,951,000	$ 29,544,000
Merck Sharp and Dohme Research Ltd.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum exercise fees and milestone payments																														$ 419,300,000
Maximum milestone payments and tiered royalties																														$ 502,500,000
Janssen Biotech, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)															0	0
Bei Gene
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)														0	0	3,530,000
Iconic Therapeutics Inc | Research and License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Portion of fee received										4,000,000
Option fee, total										20,000,000
Option fee, one time fee									5,000,000
Research Support Payments | Merck Sharp and Dohme Research Ltd.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)																													5,500,000
Research Support Payments | Eli Lilly and Company
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)																												3,000,000
Commercial Milestones | Janssen Biotech, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)																						0
Research Development and Commercial Milestones | Glaxo Smith Kline Intellectual Property Development Ltd
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)																								0
Milestone and Other Payments | Glaxo Smith Kline Intellectual Property Development Ltd | Maximum | Eligible to Receive
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)						$ 1,100,000,000
Milestone | Merck Sharp and Dohme Research Ltd.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)														0	0	2,000,000
Milestone | Eli Lilly and Company
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)														0	0	8,000,000
Milestone | Bei Gene
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)									8,000,000		$ 10,000,000		$ 5,000,000	8,000,000	15,000,000	0
Milestone | Iconic Therapeutics Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)														0	0	$ 1,000,000
Commercial and Development Milestones | Glaxo Smith Kline Intellectual Property Development Ltd
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)																									0
Commercial and Development Milestones | Daiichi Sankyo, Co., Ltd
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)																					0
Commercial and Development Milestones | LEO Pharma
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)																				0
Commercial and Development Milestones | Bei Gene
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)																			0
Milestone Payment | Iconic Therapeutics Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)																		1,000,000
Upfront Fee | Daiichi Sankyo, Co., Ltd
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)																					18,000,000
Upfront Fee | Bristol-Myers Squibb
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)												$ 12,000,000
Arrangement Other than Collaborative | Merck Sharp and Dohme Research Ltd. | Research and License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)																													1,250,000
Arrangement Other than Collaborative | Daiichi Sankyo, Co., Ltd | Maximum | Eligible to Receive | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)			$ 484,700,000
Arrangement Other than Collaborative | Development Milestone | Glaxo Smith Kline Intellectual Property Development Ltd | Maximum | Eligible to Receive | Platform Technology Transfer and License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)						183,500,000
Arrangement Other than Collaborative | Development Milestone | Daiichi Sankyo, Co., Ltd | Maximum | Eligible to Receive | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)			126,700,000
Arrangement Other than Collaborative | Commercial Milestones | Daiichi Sankyo, Co., Ltd | Maximum | Eligible to Receive | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)			$ 340,000,000
Arrangement Other than Collaborative | Technology Access Fee | Glaxo Smith Kline Intellectual Property Development Ltd | Platform Technology Transfer and License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)																								6,000,000
Arrangement Other than Collaborative | Research Milestone | Glaxo Smith Kline Intellectual Property Development Ltd | Maximum | Eligible to Receive | Platform Technology Transfer and License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)						37,500,000
Arrangement Other than Collaborative | Commercial Sales Milestones | Glaxo Smith Kline Intellectual Property Development Ltd | Maximum | Eligible to Receive | Platform Technology Transfer and License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)						$ 867,000,000
Arrangement Other than Collaborative | Royalty | Daiichi Sankyo, Co., Ltd | Eligible to Receive | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty agreement term			10 years
Arrangement Other than Collaborative | Royalty | Daiichi Sankyo, Co., Ltd | Maximum | Eligible to Receive | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage earned from sales of product			10.00%
Collaborative Arrangement | License Agreement | ZW25 and ZW49 Agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract liabilities									$ 32,941,000	$ 32,941,000				$ 32,941,000	$ 32,941,000			$ 32,941,000	$ 32,941,000	$ 32,941,000	$ 32,941,000	32,941,000	32,941,000	$ 32,941,000	$ 32,941,000	32,941,000	32,941,000	32,941,000	$ 32,941,000
Collaborative Arrangement | Maximum | Eligible to Receive | Cross License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage earned from sales of product					10.00%
Collaborative Arrangement | Eli Lilly and Company | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)																												$ 1,000,000
Collaborative Arrangement | Celgene | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)								$ 8,000,000
Collaborative agreement expansion fee								$ 4,000,000
Number of potential products to developed and commercialized | program								10
Collaborative Arrangement | Celgene | Maximum | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)								$ 164,000,000
Collaborative Arrangement | Celgene | Maximum | Eligible to Receive | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment								1,640,000,000
Collaborative Arrangement | Glaxo Smith Kline Intellectual Property Development Ltd | Maximum | Eligible to Receive | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)							$ 1,100,000,000
Collaborative Arrangement | LEO Pharma | Research and License Agreement | First Therapeutic
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments on future global net sales		20.00%
Collaborative Arrangement | Bei Gene | Research and License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Fair value of consideration allocated to a group of contracts that were considered as a single contract																	$ 20,000,000
Collaborative Arrangement | Bei Gene | Research and License Agreement | Bispecific Therapeutic
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)	$ 20,000,000
Collaborative Arrangement | Bei Gene | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of agreements | Agreement	3
Upfront payment received																	60,000,000
Fair value of consideration allocated to a group of contracts that were considered as a single contract																	40,000,000
Collaborative Arrangement | Bei Gene | License Agreement | ZW25 and ZW49 Agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments on future global net sales	20.00%
Collaborative Arrangement | Bei Gene | License Agreement | ZW25 Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Fair value of consideration allocated to a group of contracts that were considered as a single contract	$ 7,100,000
Collaborative Arrangement | Development Milestone | Celgene | Maximum | Eligible to Receive | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)								101,500,000
Collaborative Arrangement | Development Milestone | Daiichi Sankyo, Co., Ltd | Maximum | Eligible to Receive | Cross License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment					$ 63,400,000
Collaborative Arrangement | Development Milestone | Janssen Biotech, Inc. | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)																						8,000,000
Collaborative Arrangement | Development Milestone | Janssen Biotech, Inc. | Maximum | Eligible to Receive | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)				$ 274,000,000
Collaborative Arrangement | Development Milestone | LEO Pharma | Maximum | Research and License Agreement | First Therapeutic
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)		$ 74,000,000
Collaborative Arrangement | Development Milestone | LEO Pharma | Maximum | Research and License Agreement | Second Therapeutic
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)		86,500,000
Collaborative Arrangement | Commercial Milestones | Celgene | Maximum | Eligible to Receive | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)								55,000,000
Collaborative Arrangement | Commercial Milestones | Daiichi Sankyo, Co., Ltd | Maximum | Eligible to Receive | Cross License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)					80,000,000
Collaborative Arrangement | Commercial Milestones | Janssen Biotech, Inc. | Maximum | Eligible to Receive | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)				$ 1,120,000,000
Collaborative Arrangement | Commercial Milestones | LEO Pharma | Maximum | Research and License Agreement | First Therapeutic
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)		157,000,000
Collaborative Arrangement | Commercial Milestones | LEO Pharma | Maximum | Research and License Agreement | Second Therapeutic
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)		$ 157,000,000
Collaborative Arrangement | Commercial Milestones | Bei Gene | Maximum | License Agreement | ZW25 and ZW49 Agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)	390,000,000
Collaborative Arrangement | Research and Development Milestone | Eli Lilly and Company | License Agreement | Project Two
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)																											$ 10,000,000
Collaborative Arrangement | License Option | Celgene | Eligible to Receive | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)								$ 7,500,000
Collaborative Arrangement | Option Exercise Fee | Celgene | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)																										$ 7,500,000
Collaborative Arrangement | Research Development and Commercial Milestones | Glaxo Smith Kline Intellectual Property Development Ltd | Maximum | Eligible to Receive | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)							$ 110,000,000
Collaborative Arrangement | Milestone and Other Payments | Daiichi Sankyo, Co., Ltd | Maximum | Eligible to Receive | Cross License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment					$ 149,900,000
Collaborative Arrangement | Technology Access Fee | Daiichi Sankyo, Co., Ltd | Cross License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)																							2,000,000
Collaborative Arrangement | Research, Development, Commercial License Option Milestone | Daiichi Sankyo, Co., Ltd | Cross License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)																							$ 4,500,000
Collaborative Arrangement | Royalty | Janssen Biotech, Inc. | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty agreement term				10 years
Payment for royalty				$ 10,000,000
Collaborative Arrangement | License and Milestone Payments | Janssen Biotech, Inc. | Maximum | Eligible to Receive | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)				$ 1,450,000,000
Collaborative Arrangement | Commercial and Development Milestones | Bei Gene | Maximum | Research and License Agreement | Bispecific Therapeutic
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)	$ 702,000,000
Collaborative Arrangement | Upfront Fee | Janssen Biotech, Inc. | License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)																						$ 50,000,000
Collaborative Arrangement | Upfront Fee | LEO Pharma | Research and License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development collaborations (note 12)																	$ 5,000,000